Teva Stock Surges, Reaching Decade High Amid New Drug Approval
Translated & summarized from Globes by baba
Teva Pharmaceutical's stock price surged to a decade high following the FDA approval of its new schizophrenia drug, WELTRUZA. The company, which has been recovering from a massive acquisition a decade ago, is now focusing on innovation under CEO Richard Francis. Teva's pipeline includes several promising drugs with potential for over $10 billion in annual revenue, and its market capitalization has reached $47.9 billion.
The story in 6 lines · by baba
- Teva's stock price reached a decade high following FDA approval of its schizophrenia drug WELTRUZA.
- The company is recovering from a massive $40 billion acquisition that led to significant debt and restructuring.
- CEO Richard Francis is driving a strategy to transform Teva into a biopharmaceutical company focused on innovation.
- Teva's pipeline includes drugs with potential for over $10 billion in annual revenue.
- The company's market capitalization in New York reached $47.9 billion, making it the most valuable Israeli company.
- Teva has resumed acquisitions and its debt has been upgraded to investment grade.
Teva Pharmaceutical Industries' stock price surged on Friday, returning to a level not seen in nearly a decade. This rebound marks a significant turnaround for the Israeli drugmaker, which had been grappling with the aftermath of its massive $40 billion acquisition of Actavis ten years ago. That leveraged acquisition, orchestrated by former CEO Erez Vigodman, saddled Teva with substantial debt that threatened its existence.
Under former CEO Kare Schultz, Teva underwent an aggressive restructuring, including thousands of layoffs and factory closures, to stabilize its finances. The current CEO, Richard Francis, took over in 2023 with a mandate to shift Teva from years of contraction back to growth. Francis launched a strategic plan, "pivot to growth," emphasizing innovation and transforming Teva into a biopharmaceutical company.
A key development driving the stock surge is the US Food and Drug Administration's (FDA) approval of WELTRUZA (olanzapine), a novel treatment for schizophrenia. This marks the first and only monthly injectable treatment for adults with schizophrenia, offering a significant improvement in symptom management and patient function, according to Dr. Eric Hughes, Head of Global R&D and Chief Medical Officer. Analysts at Oppenheimer Israel noted the drug's significant competitive advantage due to its controlled release technology, while J.P. Morgan analyst Chris Schott raised his price target for Teva, anticipating substantial sales for WELTRUZA.
Teva's pipeline includes several innovative drugs with the potential to generate over $10 billion in annual revenue. Beyond WELTRUZA, which has an estimated peak sales potential of $1.5-$2 billion, the company is developing treatments for asthma, vitiligo, and celiac disease, with projected peak sales ranging from $1 billion to $2 billion each. A major potential blockbuster is duvakitug (anti-TL1A) for inflammatory bowel diseases, co-developed with Sanofi, which could reach $2-$5 billion in peak sales.
The company also has three notable innovative drugs already on the market: Austedo for movement disorders, Ajovy for migraines, and Uzedy for schizophrenia and bipolar disorder. Teva's market capitalization in New York reached $47.9 billion, making it the most valuable Israeli company on the stock exchange. The company has also resumed acquisitions, purchasing Emalex, which develops a treatment for Tourette syndrome in children, and its debt has been upgraded to investment grade by three international rating agencies.
Mentioned
